Biocon Ltd — Q1 FY27 earnings call
Summary generated by AI from the official transcript Biocon Ltd filed with BSE on 11 Aug 2026. Every statement cites a verbatim quote from that document — open any citation to read it. This is a record of what management said, not a recommendation. How we check these summaries
The short read
Biocon reported 10% year-on-year growth in group operating revenue for Q1 FY27, with biopharmaceuticals growing 17% while services revenue declined 16% due to lower offtake from a key biologics client. EBITDA stood at INR902 crores at a 21% margin, and reported net profit before exceptionals rose 245% year-on-year to INR145 crores. Management discussed segment performance across biosimilars, generics and Syngene, and addressed questions on profitability drivers, working capital, debt, US tariff risk, and the Bicara stake.
Numbers mentioned
Group operating revenue growth: 10% year-on-year (Q1 FY27)
p. 6
“In Q1 FY '27, the group delivered 10% year-on-year growth in operating revenue.”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
Biopharmaceuticals revenue growth: 17% year-on-year (Q1 FY27)
p. 6
“Within this, biopharmaceuticals grew 17% year-on-year with strong traction across biosimilars and generics”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
Services revenue decline: 16% year-on-year (Q1 FY27)
p. 6
“Services revenue declined 16% year-on-year due to continued impact of challenges faced the previous year.”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
EBITDA: INR902 crores (Q1 FY27)
p. 6
“EBITDA was at INR902 crores with a margin of 21%.”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
Interest cost decline: 23% year-on-year and 8% quarter-on-quarter to INR213 crores (Q1 FY27)
p. 6
“Interest cost declined 23% year-on-year and 8% quarter-on-quarter to INR213 crores following the actions taken to strengthen our balance sheet.”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
Reported net profit before exceptionals: INR145 crores, up 245% year-on-year (Q1 FY27)
p. 6
“Reported net profit for the quarter before exceptionals was INR145 crores, representing a 245% year-on-year increase.”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
Biosimilars revenue: INR2,855 crores, up 16% year-on-year (Q1 FY27)
p. 6
“Biosimilars revenue for quarter one stood at INR2,855 crores, representing a 16% year-on-year increase driven by the North America market.”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
Biosimilars EBITDA: INR728 crores, 25% margin (Q1 FY27)
p. 6
“EBITDA for the quarter stood at INR728 crores, representing a growth of 10% year-on-year and this translates into an EBITDA margin of 25%”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
Biosimilars R&D investment: 7% of revenues (Q1 FY27)
p. 6
“R&D investments for the quarter stood at 7% of revenues.”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
Generics revenue growth: 21% year-on-year (Q1 FY27)
p. 7
“Revenues stood at INR760 crores, representing a 21% year-on-year growth.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
Generics EBITDA margin: 7%, up more than 250 basis points over Q4FY26 (Q1 FY27)
p. 7
“EBITDA for the quarter stood at INR56 crores. EBITDA margin at 7% improved more than 250 basis points over Q4FY'26, driven by higher volumes and operating leverage.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
Syngene revenue decline: 16% year-on-year to INR736 crores (Q1 FY27)
p. 7
“Revenues were down 16% year-on-year to INR736 crores”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
Syngene operating EBITDA margin: 12% (Q1 FY27)
p. 7
“Operating EBITDA margin was at 12% for the quarter.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
API to formulations split in generics: 60:40 (Q1 FY27)
p. 15
“Yes. So, I think the split of API to formulations is about 60:40 this quarter.”
Kedar Upadhye, page 15 of the filed PDF · View the filing
What management said it would do
A record of statements made on the call, in the words management used. Parakho does not forecast, endorse or assess them, and their presence here is not a view on whether they will happen.
Biosimilars growth momentum — second half of FY27
stated firmly by Kiran Mazumdar Shaw
p. 6
“Q1 performance was broadly in line with our expectations, and we expect momentum to build progressively through the year with meaningful acceleration in the second half of FY'27.”
Kiran Mazumdar Shaw, page 6 of the filed PDF · View the filing
Syngene revenue — single-digit revenue degrowth in rupee terms · FY27
stated firmly by Kiran Mazumdar Shaw
p. 7
“While revenues are expected to decline in the first half, performance should improve in the second half, resulting in a single-digit revenue degrowth in rupee terms for the full year and EBITDA margins back to mid-20s.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
Syngene return to growth — profitable and sustainable growth · FY28
stated as an aspiration by Kiran Mazumdar Shaw
p. 7
“These actions are expected to position Syngene for a return to profitable and sustainable growth from FY'28.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
Biosimilars EBITDA margin
stated as an aspiration by Shreehas Tambe
p. 11
“We have always directed this to say we will be in the mid-20s, and it will ramp up.”
Shreehas Tambe, page 11 of the filed PDF · View the filing
Biosimilars margin normalization base — 24%, 25%
stated as an aspiration by Kedar Upadhye
p. 11
“So, if you normalize last year's margins to maybe 24%, 25%. Yes, then we are all driving towards margin expansion.”
Kedar Upadhye, page 11 of the filed PDF · View the filing
Aflibercept ramp-up — second half of the year
stated as an aspiration by Shreehas Tambe
p. 11
“We should have a good straight-out-the-gates a good start to this, which will build up towards the second half of the year.”
Shreehas Tambe, page 11 of the filed PDF · View the filing
Product launches in US or Europe — a new product launch either in the US or in Europe every year · till the end of the decade
stated as an aspiration by Shreehas Tambe
p. 17
“the focus has always been to see that we have a new product launch either in the US or in Europe every year from here on till the end of the decade.”
Shreehas Tambe, page 17 of the filed PDF · View the filing
Days of inventory outstanding for biosimilars — 280-290 days
stated firmly by Kedar Upadhye
p. 19
“which used to be more than 400 for biosimilars in the past, it's been normalized to about 280, 290.”
Kedar Upadhye, page 19 of the filed PDF · View the filing
Debt reduction
stated firmly by Kedar Upadhye
p. 19
“And we have said that we are working on this actively, every single dollar that we get from free cash, the first use of that is in reduction of the debt. So as things progress, you will notice the debt reduction as well.”
Kedar Upadhye, page 19 of the filed PDF · View the filing
US manufacturing capex
stated firmly by Kiran Mazumdar-Shaw
p. 20
“No, I don't believe that we will be increasing our capex in establishing new facilities or capacities in the US.”
Kiran Mazumdar-Shaw, page 20 of the filed PDF · View the filing
Q&A highlights
Management's answers to analyst questions, in Parakho's words rather than a transcript. Each row names who answered and carries the verbatim quote it was drawn from.
Management said there is nothing unusual on competitive intensity and attributed margin gains to opex reduction and integration synergies rather than pricing pressure.
Answered by Kedar Upadhye
Asked by Sidharth Negandhi: What is driving generics growth excluding liraglutide, and is the lower R&D spend versus modest EBITDA improvement a sign of competitive intensity?
p. 9
“Actually, there is nothing particularly different to call out from a competitive intensity standpoint in generics.”
Kedar Upadhye, page 9 of the filed PDF · View the filing
Management said last year's 27% was elevated due to a one-off allocation and should be normalized to 24-25%, from which they are driving margin expansion.
Answered by Kedar Upadhye
Asked by Neha Manpuria: Should biosimilar margins be assumed higher than last year's 27% given the profitable growth focus?
p. 11
“I would just, Neha, I would urge you to normalize the 27% of last year.”
Kedar Upadhye, page 11 of the filed PDF · View the filing
Management said biopharma is 83% of the business and the main growth engine, so Syngene's temporary decline should not impact overall Biocon performance.
Answered by Kiran Mazumdar Shaw
Asked by Surya Patra: Given Syngene's challenges, should investors expect moderated profitable growth for Biocon overall in FY27?
p. 12
“As, you know 83% of our business comes from Biopharmaceuticals. The Research Services business accounts for about 17%.”
Kiran Mazumdar Shaw, page 12 of the filed PDF · View the filing
Management said margin expansion across all businesses is a priority through new launches, cost improvement and operating leverage, and the API-to-formulations split is currently 60:40 versus a historical two-thirds/one-third.
Answered by Kedar Upadhye
Asked by Shyam Srinivasan: Is there a path to higher generics profitability, and how is the API-to-formulations split trending?
p. 15
“The profitability improvement is an agenda across all three businesses, Shyam.”
Kedar Upadhye, page 15 of the filed PDF · View the filing
Management declined to quantify the drag but said generics profitability improvement stems from API pricing premium, R&D portfolio optimization and opex control, with new units contributing more meaningfully over time.
Answered by Kedar Upadhye
Asked by Damayanti Kerai: What is causing the cost drag from new plant utilization, including the US unit?
p. 16
“So, I think, Damayanti, we will not call out any specific number at this stage in terms of the cost drag, but what has happened is the improvement that you're seeing in the Generics profitability is because of three things.”
Kedar Upadhye, page 16 of the filed PDF · View the filing
Management attributed the increase to inventory build for the expected second-half scale-up in biosimilars and generics, and said net debt is linked to that working capital increase rather than new term loans.
Answered by Kedar Upadhye
Asked by Ankit Shah: Why did net debt and working capital increase, and how will they trend for the rest of the year?
p. 19
“Yes, see, the increase in inventory, working capital is largely in inventory, and that's basically we are getting ready for the second-half scale-up in both biosimilars and generics.”
Kedar Upadhye, page 19 of the filed PDF · View the filing
Management said current US law exempts generics and biosimilars from tariffs, that any change would require new legislation, and framed the tariff announcement as not yet law.
Answered by Matt Erick
Asked by Chinni S: What would be the impact of tariffs announced by Trump, applicable after two years, and is Biocon improving US manufacturing capacity?
p. 20
“Right now, the law states within the United States, generics and biosimilars are exempt.”
Matt Erick, page 20 of the filed PDF · View the filing
Management said Bicara is no longer a significant investment, holding is small, and they will decide on monetization timing but are not currently contemplating it.
Answered by Kiran Mazumdar-Shaw
Asked by Vipul Shah: What is Biocon's current stake in Bicara and are there plans to monetize it?
p. 21
“The current stake is, we have a small holding in Bicara, and we are in at this moment not contemplating to monetize.”
Kiran Mazumdar-Shaw, page 21 of the filed PDF · View the filing
Risks flagged
Services business impacted by lower offtake from a key biologics client and forex hedge loss
p. 7
“Syngene's Q1 FY'27 performance was impacted by lower offtake from a key biologics client and a forex hedge loss partly offset by cost optimization initiatives.”
Kiran Mazumdar Shaw, page 7 of the filed PDF · View the filing
Price erosion and competitive forces in biosimilars market dynamics
p. 11
“It'll also help us offset the market dynamics, because price erosion is also another thing which is real in a situation in the market which will also happen.”
Shreehas Tambe, page 11 of the filed PDF · View the filing
Past performance impacted by structured debt from structured equity element
p. 12
“So, I must also remind you, Surya, that our performance in the past has been severely impacted by a lot of the structured debt that we had included in our financials because of the structured equity element, which is now retired and behind us.”
Kiran Mazumdar-Shaw, page 12 of the filed PDF · View the filing
Potential US tariffs on generics and biosimilars if legislation changes
p. 20
“So, legislation would have to be passed and redone.”
Matt Erick, page 20 of the filed PDF · View the filing
Rupee depreciation impact on dollar-denominated interest costs
p. 19
“and this is despite the rupee depreciation impact on the dollar interest that we pay.”
Kedar Upadhye, page 19 of the filed PDF · View the filing
Generated by claude-sonnet-5. Source: the transcript as filed with BSE. We link to the exchange's copy; we do not host transcripts. Parakho is a data and screening tool, not an investment adviser — nothing here is a recommendation to buy, sell or hold.